DHFR and coronary artery disorder: Methotrexate inhibits the proliferation of immunocytes by binding to DHFR. A clinical trial (NCT04616872) was conducted to evaluate the improvement of CVD of methotrexate loading by LDL-like NPs in patients with multivessel CAD. The result showed that plaque volume was decreased by the agent.